Overview

Study to Investigate the Pharmacodynamic Effects of IP2015 in Healthy Male Subjects Using the Intradermal Capsaicin Model

Status:
Not yet recruiting

Trial end date:
2022-07-01

Target enrollment:

Participant gender:

Summary

This is a Phase I, randomised, double-blind, placebo-controlled, 4-way crossover study to investigate the PD effects, safety, tolerability and PK/PD correlation of two single oral dose levels of IP2015 compared to 300 mg pregabalin and placebo in healthy male subjects using the ID capsaicin model.

Phase:

Phase 1

Details

Lead Sponsor:

Initiator Pharma

Treatments:

Pregabalin